
Sign up to save your podcasts
Or
Donaghue Woodman is the Head of Research and Development for CMG Global and Director for CannhealthMD, global pharmaceutical and educational based companies driving acceptance and change in the cannabis and psychedelic medicine space. She has more than 13 years of experience within the Pharmaceutical industry in the public and private sector. She is an MBA graduate, holds a degree in Biochemistry, Honours in Ethnopharmacology and has been awarded a scholarship in 2021 to undertake a Master’s in Psychology through Liverpool John Moores University in the UK. She is now heading the first women’s focused phase 2 psilocybin trial on the African continent.
In this episode:
You can contact Donaghue at [email protected] or 0674006894 and you can find CannSun through their website https://cannsun.com/
Donaghue Woodman is the Head of Research and Development for CMG Global and Director for CannhealthMD, global pharmaceutical and educational based companies driving acceptance and change in the cannabis and psychedelic medicine space. She has more than 13 years of experience within the Pharmaceutical industry in the public and private sector. She is an MBA graduate, holds a degree in Biochemistry, Honours in Ethnopharmacology and has been awarded a scholarship in 2021 to undertake a Master’s in Psychology through Liverpool John Moores University in the UK. She is now heading the first women’s focused phase 2 psilocybin trial on the African continent.
In this episode:
You can contact Donaghue at [email protected] or 0674006894 and you can find CannSun through their website https://cannsun.com/